Literature DB >> 33738252

A Machine Learning-Based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma.

Huapeng Lin1,2, Lingfeng Zeng3, Jing Yang1, Wei Hu1, Ying Zhu1.   

Abstract

OBJECTIVE: We sought to develop and validate a novel prognostic model for predicting survival of patients with Barcelona Clinic Liver Cancer Stages (BCLC) stage B hepatocellular carcinoma (HCC) using a machine learning approach based on random survival forests (RSF).
METHODS: We retrospectively analyzed overall survival rates of patients with BCLC stage B HCC using a training (n = 602), internal validation (n = 301), and external validation (n = 343) groups. We extracted twenty-one clinical and biochemical parameters with established strategies for preprocessing, then adopted the RSF classifier for variable selection and model development. We evaluated model performance using the concordance index (c-index) and area under the receiver operator characteristic curves (AUROC).
RESULTS: RSF revealed that five parameters, namely size of the tumor, BCLC-B sub-classification, AFP level, ALB level, and number of lesions, were strong predictors of survival. These were thereafter used for model development. The established model had a c-index of 0.69, whereas AUROC for predicting survival outcomes of the first three years reached 0.72, 0.71, and 0.73, respectively. Additionally, the model had better performance relative to other eight Cox proportional-hazards models, and excellent performance in the subgroup of BCLC-B sub-classification B I and B II stages.
CONCLUSION: The RSF-based model, established herein, can effectively predict survival of patients with BCLC stage B HCC, with better performance than previous Cox proportional hazards models.
Copyright © 2021 Lin, Zeng, Yang, Hu and Zhu.

Entities:  

Keywords:  BCLC Stage B; hepatocellular carcinoma; machine learning; prognosis; random survival forest

Year:  2021        PMID: 33738252      PMCID: PMC7962602          DOI: 10.3389/fonc.2021.608260

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  25 in total

1.  Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.

Authors:  Michael Ingrisch; Moritz Jörg Schneider; Dominik Nörenberg; Giovanna Negrao de Figueiredo; Klaus Maier-Hein; Bogdana Suchorska; Ulrich Schüller; Nathalie Albert; Hartmut Brückmann; Maximilian Reiser; Jörg-Christian Tonn; Birgit Ertl-Wagner
Journal:  Invest Radiol       Date:  2017-06       Impact factor: 6.016

2.  Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization.

Authors:  Koichiro Yamakado; Shiro Miyayama; Shozo Hirota; Kimiyoshi Mizunuma; Kenji Nakamura; Yoshitaka Inaba; Hiroaki Maeda; Kunihiro Matsuo; Norifumi Nishida; Takeshi Aramaki; Hiroshi Anai; Shinichi Koura; Shigeo Oikawa; Ken Watanabe; Taku Yasumoto; Kinya Furuichi; Masato Yamaguchi
Journal:  Jpn J Radiol       Date:  2014-03-11       Impact factor: 2.374

3.  New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Jin Hyoung Kim; Ju Hyun Shim; Han Chu Lee; Kyu-Bo Sung; Heung-Kyu Ko; Gi-Young Ko; Dong Il Gwon; Jong Woo Kim; Young-Suk Lim; Seong Ho Park
Journal:  Liver Int       Date:  2017-06-26       Impact factor: 5.828

Review 4.  Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma.

Authors:  Arndt Vogel; Anna Saborowski
Journal:  Cancer Treat Rev       Date:  2019-11-29       Impact factor: 12.111

5.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

Authors:  L Kadalayil; R Benini; L Pallan; J O'Beirne; L Marelli; D Yu; A Hackshaw; R Fox; P Johnson; A K Burroughs; D H Palmer; T Meyer
Journal:  Ann Oncol       Date:  2013-07-14       Impact factor: 32.976

Review 6.  From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.

Authors:  Dimitrios Dimitroulis; Christos Damaskos; Serena Valsami; Spyridon Davakis; Nikolaos Garmpis; Eleftherios Spartalis; Antonios Athanasiou; Demetrios Moris; Stratigoula Sakellariou; Stylianos Kykalos; Gerasimos Tsourouflis; Anna Garmpi; Ioanna Delladetsima; Konstantinos Kontzoglou; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2017-08-07       Impact factor: 5.742

7.  Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data.

Authors:  Lujun Shen; Qi Zeng; Pi Guo; Jingjun Huang; Chaofeng Li; Tao Pan; Boyang Chang; Nan Wu; Lewei Yang; Qifeng Chen; Tao Huang; Wang Li; Peihong Wu
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

Review 8.  Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.

Authors:  Tatsuo Kanda; Taichiro Goto; Yosuke Hirotsu; Mitsuhiko Moriyama; Masao Omata
Journal:  Int J Mol Sci       Date:  2019-03-18       Impact factor: 5.923

9.  Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Authors:  Young Eun Chon; Hana Park; Hye Kyung Hyun; Yeonjung Ha; Mi Na Kim; Beom Kyung Kim; Joo Ho Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Seong Gyu Hwang; Kwang-Hyub Han; Kyu Sung Rim; Jun Yong Park
Journal:  Cancers (Basel)       Date:  2019-04-10       Impact factor: 6.639

10.  Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma.

Authors:  Xueping Wang; Minjie Mao; Zhonglian He; Lin Zhang; Huilan Li; Jianhua Lin; Yi He; Shuqin Dai; Wanming Hu; Wanli Liu
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

View more
  3 in total

Review 1.  CircRNAs: novel therapeutic targets in multiple myeloma.

Authors:  Xinyi Zhou; Juan Du
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.316

2.  MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.

Authors:  Wei Pei; Chen Wang; Hai Liao; Xiaobo Chen; Yunyun Wei; Xia Huang; Xueli Liang; Huayan Bao; Danke Su; Guanqiao Jin
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

3.  Serum hsa_circ_0087776 as a new oncologic marker for the joint diagnosis of multiple myeloma.

Authors:  Xingxing Gong; Xu Lu; Jing Cao; Huan Liu; Hongmei Chen; Fang Bao; Xiuying Shi; Hui Cong
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.